Greenberg Traurig Represents BillionToOne Inc. in $314M Initial Public Offering

HOUSTON - Dec. 11 2025 - Global law firm Greenberg Traurig, LLP represented BillionToOne Inc., a precision diagnostics company, on regulatory matters in connection with its initial public offering (IPO), which raised $314 million in gross proceeds. The IPO, completed Nov. 7, priced shares (Nasdaq: BLLN) at $60, above the initial range of $49 to $55 per share.

"We are honored to offer our legal guidance to the BillionToOne team as it entered the public markets," said Health Care & FDA Shareholder Charles C. Dunham, IV, who leads Greenberg Traurig's team representing BillionToOne. "We look forward to continuing to support BillionToOne with its legal and regulatory needs as it works to advance innovative diagnostic and predictive solutions that benefit patients and health care providers worldwide."

At the IPO price, BillionToOne achieved a market capitalization of $2.75 billion. By the close of its first day of trading, the company's shares surged 82%, to $109 each, increasing its market cap to $5 billion and underscoring the market's strong endorsement of its mission to advance molecular diagnostics.

According to its website, BillionToOne's mission is to make molecular diagnostics more accurate, efficient, and accessible. Its proprietary molecular counting platform can accurately count DNA molecules at the single-count level to help improve disease detection.

Read more: BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares.